---
title: "Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293395375.md"
description: "The NMPA has approved the supplemental application for the use of Toripalimab in combination with chemotherapy as a perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC. This decision allows for the treatment to be used in patients with these specific stages of non-small cell lung cancer."
datetime: "2026-07-21T23:12:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293395375.md)
  - [en](https://longbridge.com/en/news/293395375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293395375.md)
generator: "portal-rs"
---

# Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC

The NMPA has approved the supplemental application for the use of Toripalimab in combination with chemotherapy as a perioperative treatment for resectable stage Ⅱ-Ⅲ NSCLC. This decision allows for the treatment to be used in patients with these specific stages of non-small cell lung cancer.

### Related Stocks

- [01877.HK](https://longbridge.com/en/quote/01877.HK.md)
- [688180.CN](https://longbridge.com/en/quote/688180.CN.md)

## Related News & Research

- [Shanghai Junshi says China regulator accepts label expansion filing for toripalimab chemo in resectable stage II-III NSCLC](https://longbridge.com/en/news/293348759.md)
- [Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung Cancer](https://longbridge.com/en/news/293373812.md)
- [04:03 ETDizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026](https://longbridge.com/en/news/296585269.md)
- [Leads Biolabs touts promising Phase II data for NSCLC bispecific antibody LBL-024](https://longbridge.com/en/news/296415546.md)
- [VibroSense wins Japan patent for chemotherapy-induced neuropathy biomarker](https://longbridge.com/en/news/295890805.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**